Is an immediate release formulation of Vyvanse (lisdexamfetamine) available?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 19, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Vyvanse Immediate Release Availability

No, Vyvanse (lisdexamfetamine) is not available in an immediate-release formulation and cannot be made into one due to its unique prodrug design.

Why Immediate Release Is Not Possible

  • Lisdexamfetamine is specifically engineered as a prodrug that requires enzymatic conversion in the blood to become active. The molecule remains therapeutically inactive until red blood cells hydrolyze it to release d-amphetamine and L-lysine through a rate-limited process 1, 2.

  • The conversion mechanism is inherently delayed compared to immediate-release amphetamine formulations, making it impossible to create a true immediate-release version of lisdexamfetamine itself 1.

  • Alternative routes of administration (such as crushing or dissolving) do not bypass the required enzymatic conversion, as the prodrug must still undergo hydrolysis in the bloodstream to become pharmacologically active 1.

Available Amphetamine Formulations

If you need an immediate-release amphetamine option, consider these alternatives:

  • Dexedrine (dextroamphetamine) immediate release is available and typically dosed starting at 5 mg twice daily 3.

  • Adderall immediate release (mixed amphetamine salts) provides immediate-release amphetamine effects with standard dosing flexibility 3.

  • Liquid dextroamphetamine formulations offer precise dose titration and are particularly useful for patients requiring dosing flexibility, though they carry higher risk of rebound effects compared to long-acting formulations 3.

Clinical Implications of Vyvanse's Design

  • The prodrug design of lisdexamfetamine results in lower abuse potential compared to immediate-release formulations, with pharmacokinetic properties that make extraction of the stimulant component more difficult 4, 5.

  • Lisdexamfetamine demonstrates significantly less abuse/misuse in poison center data, with odds of abuse 2.3 times lower than immediate-release dextroamphetamine/amphetamine 5.

  • Vyvanse is dosed once daily in the morning, starting at 20-30 mg with weekly titration by 10 mg increments up to a maximum of 70 mg daily 4.

References

Guideline

Pharmacokinetics of Lisdexamfetamine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Liquid Amphetamine Formulations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Placental Transfer of Vyvanse

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.